Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in G3 gastroenteropancreatic neuroendocrine neoplasms
CTR20180291Phase 2Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in Gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started May 2018; status: active.
02
Drugs
anlotinib
03
Conditions
Gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN)
Beyond the preview
Go deeper on CTR20180291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180291.